NanoVibronix, Inc. engages in the development of noninvasive biological response-activating devices. The company is headquartered in Tyler, Texas and currently employs 15 full-time employees. The company went IPO on 2015-04-24. The technology allows for the creation of low-frequency ultrasound waves that can be utilized for a variety of medical applications, including for disruption of biofilms and bacterial colonization, as well as for pain relief. The firm's primary products include PainShield and UroShield, which are portable devices suitable for administration at home or in any care setting. PainShield is a patch-based therapeutic ultrasound technology to treat pain, muscle spasm and joint contractures by delivering a localized ultrasound effect to treat pain and induce soft tissue healing in a targeted area. UroShield is an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters, increase antibiotic efficacy and decrease pain and discomfort associated with urinary catheter use.
Leveraging in-depth analyst evaluations, we have synthesized key insights from expert assessments to present a positive outlook for NAOV. Analysts highlight solid fundamentals and favorable market sentiment, suggesting upside potential in the near term. Based on this thorough expert analysis, we maintain an optimistic view of this stock. Our conclusion: NAOV is a Buy candidate.
NAOV stock price ended at $1.46 on 星期四, after dropping 14.12%
On the latest trading day Jan 15, 2026, the stock price of NAOV fell by 14.12%, dropping from $1.54 to $1.46. During the session, the stock saw a volatility of 11.35%, with prices oscillating between a daily low of $1.41 and a high of $1.57. On the latest trading day, the trading volume for NAOV decreased by 21.9M shares, aligning with the declining prices, which may indicate weakening market confidence in the near term. In total, 755.6K shares were traded, with a market value of approximately $1.5M.